Abstract
Discussion. Oncogenic osteomalacia is a rare paraneoplastic syndrome of skeletal demineralization from renal phosphate loss. Patients with this disorder have the characteristic clinical, laboratory, and radiographic findings of hyperphosphaturic osteomalacia. Although the pathophysiology has not yet been clearly delineated, a humoral factor produced by the tumor is suspected to be the cause.
Purpose. We report the first case of oncogenic osteomalacia that improved with chemotherapy, discuss this paraneoplastic syndrome, and review the medical literature regarding its etiology.
Full Text
The Full Text of this article is available as a PDF (206.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aschinberg L. C., Solomon L. M., Zeis P. M., Justice P., Rosenthal I. M. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr. 1977 Jul;91(1):56–60. doi: 10.1016/s0022-3476(77)80444-7. [DOI] [PubMed] [Google Scholar]
- Cai Q., Hodgson S. F., Kao P. C., Lennon V. A., Klee G. G., Zinsmiester A. R., Kumar R. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994 Jun 9;330(23):1645–1649. doi: 10.1056/NEJM199406093302304. [DOI] [PubMed] [Google Scholar]
- Miyauchi A., Fukase M., Tsutsumi M., Fujita T. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. J Clin Endocrinol Metab. 1988 Jul;67(1):46–53. doi: 10.1210/jcem-67-1-46. [DOI] [PubMed] [Google Scholar]
- Nelson A. E., Namkung H. J., Patava J., Wilkinson M. R., Chang A. C., Reddel R. R., Robinson B. G., Mason R. S. Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol. 1996 Nov 29;124(1-2):17–23. doi: 10.1016/s0303-7207(96)03928-7. [DOI] [PubMed] [Google Scholar]
- Rossi R., Gödde A., Kleinebrand A., Riepenhausen M., Boos J., Ritter J., Jürgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994 Jan;12(1):159–165. doi: 10.1200/JCO.1994.12.1.159. [DOI] [PubMed] [Google Scholar]
- Seshadri M. S., Cornish C. J., Mason R. S., Posen S. Parathyroid hormone-like bioactivity in tumours from patients with oncogenic osteomalacia. Clin Endocrinol (Oxf) 1985 Dec;23(6):689–697. doi: 10.1111/j.1365-2265.1985.tb01130.x. [DOI] [PubMed] [Google Scholar]
- Stone M. D., Quincey C., Hosking D. J. A neuroendocrine cause of oncogenic osteomalacia. J Pathol. 1992 Jun;167(2):181–185. doi: 10.1002/path.1711670204. [DOI] [PubMed] [Google Scholar]
- Wilkins G. E., Granleese S., Hegele R. G., Holden J., Anderson D. W., Bondy G. P. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab. 1995 May;80(5):1628–1634. doi: 10.1210/jcem.80.5.7745010. [DOI] [PubMed] [Google Scholar]